Across TCGA pan-cancer cohorts, NAB1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NAB1 data layer compared with 26 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NAB1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated NAB1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.
PDAC, CCRCC, and HNSC are the cancer types where NAB1 mass-spec protein most reproducibly stratifies survival.